FTC to Scrutinize Improper Drug Patent Listings in Orange Book
- September 15, 2023
Improper patent listings of brand-name drugs in the Food and Drug Administration’s (FDA’s) “Orange Book” may be viewed as unfair methods of competition under federal antitrust law, the Federal Trade Commission (FTC) warned pharmaceutical companies in a policy statement issued September 14.
ARTICLE TAGS
You must be logged in to access this content.